BioAtla, Inc. (BCAB) News

BioAtla, Inc. (BCAB): $1.71

0.04 (-2.29%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add BCAB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#158 of 341

in industry

Filter BCAB News Items

BCAB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BCAB News Highlights

  • For BCAB, its 30 day story count is now at 6.
  • Over the past 18 days, the trend for BCAB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DEC, ADC and AXL are the most mentioned tickers in articles about BCAB.

Latest BCAB News From Around the Web

Below are the latest news stories about BIOATLA INC that investors may wish to consider to help them evaluate BCAB as an investment opportunity.

Co-Founder of BioAtla Jay Short Buys 2.3% More Shares

Investors who take an interest in BioAtla, Inc. ( NASDAQ:BCAB ) should definitely note that the Co-Founder, Jay Short...

Yahoo | December 23, 2023

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the 42nd Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, CA January 8-11, 2024. Format: Fireside chat and scheduled

Yahoo | December 20, 2023

After losing 78% in the past year, BioAtla, Inc. (NASDAQ:BCAB) institutional owners must be relieved by the recent gain

Key Insights Significantly high institutional ownership implies BioAtla's stock price is sensitive to their trading...

Yahoo | December 15, 2023

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher doses Ongoing Phase 2 clinical study of monotherapy and in combination with a PD-1 inhibitor SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today is hosting a v

Yahoo | December 13, 2023

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual R&D Day on Wednesday, December 13, 2023 at 10:00 AM ET. To register, click here. The event will feature Omid Hamid, MD (Cedars Sinai: The Angeles Clinic and Research Institute), who will review Phase 1 dose escalation

Yahoo | December 6, 2023

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

Results from the Phase 2 BA3011 clinical non-small cell lung cancer (NSCLC) study demonstrated promising clinical benefits in heavily pre-treated non-squamous histology patients across key endpoints BA3011 is a CAB-AXL antibody-drug conjugate (ADC) being studied in refractory NSCLC patients SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics

Yahoo | December 5, 2023

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and scheduled one-on-one investor meetings at the JMP Securities Hematology and Oncology Summit, to be held virtually December 5–6, 2023. Format: Fireside chat and scheduled

Yahoo | November 30, 2023

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual KOL Event on Monday, December 4, 2023 at 11:00 AM ET. To register, click here. The event will feature Carl M. Gay, MD, PhD (MD Anderson Cancer Center), who will review the Phase 2 clinical trial data of mecbotamab ved

Yahoo | November 28, 2023

BioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Call Transcript

BioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the BioAtla Third Quarter 2023 Earnings Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] Please be advised that this call is […]

Yahoo | November 12, 2023

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

Observed additional clinical responses and FDA feedback supports path forward for CAB-AXL-ADC (BA3011) non-small cell lung cancer (NSCLC) registrational study; detailed interim Phase 2 data to be presented at upcoming IASLC conference in early December and discussed at KOL event on December 4, 2023Observed new PRs with CAB-ROR2-ADC (BA3021) Q2W dosing regimen in the Phase 2 melanoma study and a new PR with BA3021 2Q3W in the Phase 2 head and neck studyInitiated Phase 2 CAB-CTLA-4 (BA3071) study;

Yahoo | November 7, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!